Drugs / Oxidized tumor Cell Lysate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01312389 | Apr 2011 → May 2012 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Abramson Cancer Center at Penn Medicine | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oxidized tumor Cell Lysate | “OC-L, an autologous vaccine comprised of autologous Oxidized tumor Cell Lysate (OC-L) administered by intradermal/subcutaneous injection” NCT01312389 ↗ |
| Known as | OC-L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01312389 ↗ |
| Modality | Vaccine | “an autologous vaccine comprised of autologous Oxidized tumor Cell Lysate (OC-L)” NCT01312389 ↗ |